These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17692534)

  • 41. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
    Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL
    J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
    Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
    J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
    Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
    J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Designing out disulfide bonds of leech carboxypeptidase inhibitor: implications for its folding, stability and function.
    Arolas JL; Castillo V; Bronsoms S; Aviles FX; Ventura S
    J Mol Biol; 2009 Sep; 392(2):529-46. PubMed ID: 19559710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of interactions between urokinase plasminogen and inhibitors using molecular dynamic simulation and free-energy calculation.
    Sa R; Fang L; Huang M; Li Q; Wei Y; Wu K
    J Phys Chem A; 2014 Oct; 118(39):9113-9. PubMed ID: 24984238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase.
    Ruppert C; Mahavadi P; Wygrecka M; Weaver TE; Magdolen V; Idell S; Preissner KT; Seeger W; Günther A; Markart P
    Thromb Haemost; 2008 Dec; 100(6):1185-92. PubMed ID: 19132247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure, function and antagonists of urokinase-type plasminogen activator.
    Vincenza Carriero M; Franco P; Vocca I; Alfano D; Longanesi-Cattani I; Bifulco K; Mancini A; Caputi M; Stoppelli MP
    Front Biosci (Landmark Ed); 2009 Jan; 14(10):3782-94. PubMed ID: 19273310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion.
    Elia C; Cassol E; Sidenius N; Blasi F; Castagna A; Poli G; Alfano M
    J Leukoc Biol; 2007 Nov; 82(5):1212-20. PubMed ID: 17704294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.
    Wendt MD; Geyer A; McClellan WJ; Rockway TW; Weitzberg M; Zhao X; Mantei R; Stewart K; Nienaber V; Klinghofer V; Giranda VL
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3063-8. PubMed ID: 15149645
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines.
    Barber CG; Dickinson RP; Horne VA
    Bioorg Med Chem Lett; 2002 Jan; 12(2):181-4. PubMed ID: 11755349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of urokinase-type plasminogen activator in the acquisition, expression and reinstatement of cocaine-induced conditioned-place preference.
    Bahi A; Kusnecov AW; Dreyer JL
    Behav Brain Res; 2008 Aug; 191(1):17-25. PubMed ID: 18436315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
    J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bicyclic peptide inhibitor reveals large contact interface with a protease target.
    Angelini A; Cendron L; Chen S; Touati J; Winter G; Zanotti G; Heinis C
    ACS Chem Biol; 2012 May; 7(5):817-21. PubMed ID: 22304751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
    Salvi A; Sabelli C; Moncini S; Venturin M; Arici B; Riva P; Portolani N; Giulini SM; De Petro G; Barlati S
    FEBS J; 2009 Jun; 276(11):2966-82. PubMed ID: 19490101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Posttranscriptional regulation of urokinase receptor expression by heterogeneous nuclear ribonuclear protein C.
    Velusamy T; Shetty P; Bhandary YP; Liu MC; Shetty S
    Biochemistry; 2008 Jun; 47(24):6508-17. PubMed ID: 18494499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
    Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
    J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.
    Joossens J; Ali OM; El-Sayed I; Surpateanu G; Van der Veken P; Lambeir AM; Setyono-Han B; Foekens JA; Schneider A; Schmalix W; Haemers A; Augustyns K
    J Med Chem; 2007 Dec; 50(26):6638-46. PubMed ID: 18052026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.